Benzinga | Jan 7, 2022 04:03PM EST

Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte (TIL) cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT(tm) and CIBMTR(r), to be held February 2 6, 2022 in Salt Lake City, Utah, and virtually. Details for the abstracts are as follows:

Title: Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from AustraliaPresenting Author: Anandaraman Veerapathran, Iovance BiotherapeuticsPresentation Type: PosterAbstract ID: 287

Title: Decitabine Treatment of Tumor-Infiltrating Lymphocytes (TIL) during Ex Vivo Expansion Induces a More Memory-like Phenotype, Reduces Inhibitory Receptor Expression, and Increases FunctionalityPresenting Author: Rafael Cubas, Iovance BiotherapeuticsPresentation Type: PosterAbstract ID: 270

Poster Display Hours: Wednesday, February 2, 2022 from 10:00 am to 8:00 pm; Thursday, February 3, 2022 from 7:00 am to 8:15 pm; Friday, February 4, 2022 from 7:00 am to 8:00 pm; and Saturday, February 5, 2022 from 7:00 am to 7:45 pm (all times MST)

Poster Receptions: Thursday, February 3, 2022 from 6:45 pm to 8:15 pm MST and Saturday, February 5, 2022 from 6:15 pm to 7:45 pm MST